Kladribin

Из Википедије, слободне енциклопедије
Иди на навигацију Иди на претрагу
Kladribin
Cladribine.svg
Klinički podaci
Prodajno imeLeustatin, Mylinax
Drugs.comMonografija
Način primeneIntravenozno
Farmakokinetički podaci
Poluvreme eliminacije5,4 h
Identifikatori
CAS broj4291-63-8 ДаY
ATC kodL01BB04 (WHO)
PubChemCID 20279
DrugBankDB00242 ДаY
ChemSpider19105 ДаY
ChEBICHEBI:567361 ДаY
ChEMBLCHEMBL1619 ДаY
Hemijski podaci
FormulaC10H12ClN5O3
Molarna masa285,687
Fizički podaci
Tačka topljenja215 °C (419 °F)

Kladribin je organsko jedinjenje, koje sadrži 10 atoma ugljenika i ima molekulsku masu od 285,687 Da.[1][2][3][4][5][6][7][8][9]

Osobine[уреди]

Osobina Vrednost
Broj akceptora vodonika 7
Broj donora vodonika 3
Broj rotacionih veza 2
Particioni koeficijent[10] (ALogP) -0,3
Rastvorljivost[11] (logS, log(mol/L)) -1,3
Polarna površina[12] (PSA, Å2) 119,3

Reference[уреди]

  1. ^ Warnke C, Wiendl H, Hartung HP, Stuve O, Kieseier BC: Identification of targets and new developments in the treatment of multiple sclerosis - focus on cladribine. Drug Des Devel Ther. 2010 Jul 21;4:117-26. PMID 20689698
  2. ^ Sigal DS, Miller HJ, Schram ED, Saven A: Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood. 2010 Jul 15. PMID 20634380
  3. ^ Khalid BA, Hamilton NT, Cauchi MN: Binding of thyroid microsomes by lymphocytes from patients with thyroid disease and normal subjects. Clin Exp Immunol. 1976 Jan;23(1):28-32. PMID 1261088
  4. ^ Sampat K, Kantarjian H, Borthakur G: Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs. 2009 Oct;18(10):1559-64. PMID 19715446
  5. ^ Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S: Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30. PMID 17852710
  6. ^ Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. Epub 2009 Jul 1. PMID 19576186
  7. ^ Larson ML, Venugopal P: Clofarabine: a new treatment option for patients with acute myeloid leukemia. Expert Opin Pharmacother. 2009 Jun;10(8):1353-7. PMID 19463072
  8. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126. 
  9. ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958. 
  10. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  11. ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. 
  12. ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. 

Literatura[уреди]

Spoljašnje veze[уреди]

Star of life.svgMolimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).